



## PRESS RELEASE

### **Institut de Cancérologie Gustave Roussy (France) and M. D. Anderson (USA) invite attendees to a major innovative scientific event: an open interactive symposium dedicated to personalized cancer care, to be held in Paris, 9<sup>th</sup> and 10<sup>th</sup> July, 2009**

**Villejuif, France, May 5th, 2009**

The Institut de Cancérologie Gustave Roussy (IGR), Villejuif, France, and The University of Texas M. D. Anderson Cancer Center, Houston, USA, in association with several other leading cancer care institutions in Europe, the United States of America, Canada, and Asia, are organizing an open interactive symposium dedicated exclusively to personalized cancer care. This major event will be held at the Palais de Congrès, in Paris, on July 9-10<sup>th</sup>, 2009.

The symposium, entitled; Worldwide Innovative Networking in Personalized Cancer Medicine (WIN), emphasizes complex interactions between researchers, clinicians, technology developers, biotechnology and pharmaceutical industry. The symposium program will include sessions dedicated to strategic vision, advanced scientific concepts, and technological developments, as well as major achievements in personalized cancer medicine and associated international networking challenges. The symposium will feature an open interactive forum between attendees and invited speakers: all registered attendees are invited to submit questions relative to unmet needs in personalized cancer care (register online at [www.mfcongres.com](http://www.mfcongres.com)).

*“Early diagnosis and early personalized treatment will be the most efficient approach to modifying the outcome of cancer and significantly decreasing global mortality rates. International cooperation such as those encouraged by this symposium is a crucial factor for achieving these goals within the next 5 years, rather than waiting for 20 more years”* said Prof Thomas Tursz, General Director of Institut Gustave Roussy.

*“Advancing cancer care towards personalized medicine is a major clinical, scientific, and economic challenge and will require us to decrease the time that it takes from discoveries in cancer cell genetics and biology to real changes in current therapies for cancer patients that offer better outcomes,”* said John Mendelsohn, M.D., President of M. D. Anderson.

Academic organizers of this scientific symposium, together with their associated technology partners, look forward to welcoming you to this event. For your information, the program of the symposium is attached.

### **About Institut Gustave Roussy**

The Institut Gustave Roussy (IGR, Villejuif, France), one of Europe's leading Comprehensive Cancer Centers, is a non-profit academic entity belonging to the French public hospital organization. IGR is a center wholly patient-oriented with a global expertise and the mission to fight cancer. Located south of Paris on a single site, IGR employs 2,000 professionals working in care, research, and teaching. Some IGR figures: 368 inpatient beds and places for ambulatory, 159 certified physicians, 751 professional of care, 161,000 consultations and 43,000 patients cared per year, 14 basic research units, 300 research scientists, and 260 students, researchers and physicians trained per year. For more information visit [www.igr.fr](http://www.igr.fr).

### **About M. D. Anderson**

[The University of Texas M. D. Anderson Cancer Center](http://www.mdanderson.org) in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For four of the past six years, including 2008, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

 [Get M. D. Anderson News Via RSS](#)  [Follow M. D. Anderson News on Twitter](#)

**MD Anderson Cancer Center ([www.mdanderson.org](http://www.mdanderson.org))**  
**Press office: Wendy Gottsegen, 713-794-1584**  
**[externalcommunications@mdanderson.org](mailto:externalcommunications@mdanderson.org)**

**Institut Gustave Roussy ([www.igr.fr](http://www.igr.fr))**  
**Press office: Chloe Louys, +33 1 42 11 50 59**  
**e-mail: [chloe.louys@igr.fr](mailto:chloe.louys@igr.fr)**



**kdm communications limited ([www.kdm-communications.com](http://www.kdm-communications.com))**  
**Sarah Khan : +44.1234.210555**  
**e-mail: [sarahk@kdm-communications.com](mailto:sarahk@kdm-communications.com)**



**MF Congres ([www.mfcongres.com](http://www.mfcongres.com))**  
**Michael Bia: +33 1 40 07 11 21**  
**e-mail: [mbia@fr.oleane.com](mailto:mbia@fr.oleane.com)**

## **Invited speakers participating in the open interactive symposium**

Richard L. Schilsky, University of Chicago Medical Center, Chicago, USA  
Thomas Tursz, Institut Gustave Roussy, Villejuif, France  
Leroy Hood, Institute for System Biology, Seattle, USA  
Julio E. Celis, Institute of Cancer Biology, Copenhagen, Denmark  
Stanley Hamilton, MD Anderson Cancer Center, Houston, USA  
Ulrik Ringborg, Karolinska Institutet, Stockholm, Sweden  
Ignacio I. Wistuba, MD Anderson Cancer Center, Houston, USA  
Stephen Friend, Sage, Seattle, USA  
Olli Kallioniemi, Institute For Molecular Medicine, University of Helsinki, Finland  
Guo-Liang Jiang, Shanghai Cancer Center, Fudan University, Shanghai, China  
George Simon, Fox Chase Cancer Center, Philadelphia, USA  
Robert Sigal, GE Healthcare, Paris, France  
Manfred Schmitt, Technische Universitaet Muenchen, Munich, Germany  
Juri Gelovani, MD Anderson Cancer Center, Houston, USA  
René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands  
Giles Vassal, Institut Gustave Roussy, Villejuif, France  
Lu Yiming, RuiJin Hospital and University Medical School, Shanghai, China  
Vladimir Lazar, Institut Gustave Roussy, Villejuif, France  
Neil Cook, Agilent Technologies, Santa Clara, USA  
Rolf Lewensohn, KBC, Karolinska Institutet, Stockholm, Sweden  
Joost van den Oord, Katholieke Universiteit Leuven, University Hospitals, Leuven, Belgium  
Lajos Pusztai, MD Anderson Cancer Center, Houston, Texas  
Marco Pierotti, Istituto Nazionale dei Tumori, Milan, Italy  
Anil Potti, Duke University, Durham, USA  
Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France  
Anton Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands  
Alan Spatz, Segal Cancer Center, Jewish General Hospital, Montreal, Canada  
Johan De-Bonno, Royal Marsden Hospital, London, United Kingdom  
Joakim Lundeberg, Royal Institute for Technology, Stockholm, Sweden  
Fabrice André, Institut Gustave Roussy, Villejuif, France  
Zohar Yakhini, Agilent Laboratories and Technion, Haifa, Israel  
Simone Guenther, Applied Biosystems, Foster City, USA  
Johan Hanson, Karolinska Institutet, Stockholm, Sweden  
Richard Booton, The Christie and Manchester Cancer Research Centre, Manchester, United Kingdom

## **Academic organizers of the WIN network symposium**

- Institut Gustave Roussy (IGR), Villejuif (France)
- MD Anderson Cancer Center (MDACC), Houston (USA)
- Karolinska Institutet (KI), Stockholm (Sweden)
- Fox Chase Cancer Center (FCCC), Philadelphia (USA)
- Duke University, Durham (USA)

- Segal Cancer Center, Jewish General Hospital, Montréal (Canada)
- Institute for Molecular Medicine (FIMM) University of Helsinki, Helsinki (Finland)
- Technische Universitaet Muenchen (TUM), Munich (Germany)
- Royal Institute for Technology (KTH), Stockholm (Sweden)
- Katholieke Universiteit Leuven, University Hospitals, Leuven (Belgium)
- Istituto Nazionale dei Tumori, Milan (Italy)
- Shanghai Cancer Center, FUDAN University, Shanghai (China)
- RuiJin Hospital and University Medical School, Shanghai (China)
- Centro Nacional de Investigaciones Oncologica (CNIO), Madrid (Spain)
- The Christie and Manchester Cancer Research Centre, Manchester, United Kingdom

**Associate Technology partners, and co-organizers and sponsors of the WIN network symposium**

- Agilent Technologies, Santa Clara (USA)
- GE Healthcare, Chalfont St Giles (UK)
- Applied Biosystems, Foster City (USA)